

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number
WO 2004/082485 A1

- (51) International Patent Classification⁷: **A61B 10/00**
- (21) International Application Number:
PCT/EP2004/002703
- (22) International Filing Date: 16 March 2004 (16.03.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0306127.2 18 March 2003 (18.03.2003) GB
- (71) Applicant (for all designated States except US): **WIL-LETT INTERNATIONAL LIMITED** [GB/GB]; 3 Cronin Road, Weldon South Industrial Estate, Corby, Northamptonshire NN18 8AQ (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **FOX, Michael, James** [GB/GB]; 13 Church Lane, Seaton, Near Oakham, Rutland LE15 9HR (GB).
- (74) Agent: **MCGOWAN, Nigel, George**; Intellectual Property Department, Siemens Shared Services, Siemens House, Oldbury, Bracknell, Berkshire RG12 8FZ (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A DEVICE FOR NON-INVASIVELY DETECTING OR MONITORING A MEDICAL CONDITION IN A MAMMAL



(57) Abstract: A device for non-invasively detecting or monitoring a medical condition in a mammal, said device comprising a member (2, 3, 10) adapted to be worn upon the body of the mammal to receive at least some of a bodily fluid excreted by the mammal, said member carrying one or more marker ingredients (4) which interact with one or more components of the bodily fluid to generate a colour or other visible indication, said interaction being characteristic of the medical condition in the mammal.

A DEVICE FOR NON-INVASIVELY DETECTING OR MONITORING A
MEDICAL CONDITION IN A MAMMAL

The present invention relates to a device for non-
5 invasively detecting or monitoring a medical condition in
a mammal.

BACKGROUND TO THE INVENTION:

10 In order to detect or monitor a medical condition in a
human being or other mammal, it is often necessary to draw
a sample of the blood of the mammal and to subject that to
one or more tests to identify an illness or condition from
which the mammal is suffering or to monitor the progress
15 or that condition, for example its response to treatment.
Many of such conditions also evidence themselves by way of
the presence or absence of constituents in the urine or
other bodily fluid excreted by the mammal so that
collection of a sample of the bodily fluid and analysis or
20 testing of that fluid can also be used to identify or
monitor the condition. However, such methods are invasive
in the case of taking blood samples or require collection
of a sample of the excreted bodily fluid, which is
cumbersome and often overlooked by the patient.

25 We have now devised a method for detecting or monitoring a
medical condition in a mammal which reduces the above
problems and provides simple and effective monitoring or
detecting which is non-invasive and does not require
30 conscious effort by the patient.

- 2 -

SUMMARY OF THE INVENTION:

Accordingly, the present invention provides a non-invasive
5 method for detecting or monitoring a medical condition in
a mammal, which method comprises detecting a visual and/or
colour change in a marker ingredient which interacts with
one or more components of a bodily fluid excreted by the
mammal to generate a colour or other visible indication
10 which interaction is characteristic of a medical condition
in the mammal, the marker ingredient being carried by a
carrier member worn by the mammal and which receives at
least part of the bodily fluid excreted by the mammal.

15 The invention also provides a device for use in the method
of the invention, which device comprises a member adapted
to be worn upon the body of a mammal and to receive at
least some of the bodily fluid to be assessed, the member
carrying one or more marker ingredients which interact
20 with one or more components of the bodily fluid to
generate a colour or other visible indication which
interaction is characteristic of a medical condition in
the mammal.

25 The invention can be applied to detecting and/or
monitoring a wide range of medical conditions in a range
of mammals, for example kidney disorders in domestic
animals, cattle or horses. However, the invention is of
especial application in the monitoring and/or detection of
30 medical conditions in humans, including the excretion of

- 3 -

drug residues or metabolites and for convenience will hereinafter be described in terms of this preferred application.

5 The invention can be applied to the monitoring of an existing condition by detecting fluctuations in the interaction between the bodily fluid and a known level of marker ingredients on the carrier member. Alternatively, the invention can be applied to the routine screening of
10 patients to detect an infection or malfunction of an organ. It is particularly preferred that the body fluid which is contacted with the marker ingredient be urine, but the fluid may be any other which can be conveniently collected by the carrier member and for which a marker
15 ingredient gives a visible interaction which can be related to the existence or severity of a condition in the patient. For convenience, the invention will be described hereinafter in terms of testing the urine of a patient.

20 The invention is of especial benefit where there is patient resistance to the use of conventional non-invasive techniques. For example, the invention can be used with babies, infants, the aged or infirm where the collection of clean urine samples is difficult or where the patient
25 readily overlooks or fails to carry out a routine testing programme. By collecting the urine and testing that, once the patient is persuaded to wear the carrier member, testing of the urine is inherent at each urination.

30 The invention can be applied to the detection of a wide

- 4 -

range of components of the excreted bodily fluid which are indicators or medical conditions in humans. Thus, the invention can be applied to detecting sugars and sugar levels in the urine of a patient undergoing treatment for diabetes, to detecting urea, white blood cells or other indicators of infections and/or failure of the kidney or liver, cancer tumour markers, or blood in the urine. Marker ingredients for monitoring or detecting such and other conditions are commercially available and may be used in their commercially available forms in the present invention. The marker ingredients may be ones which interact directly with a component of the urine, for example in the detection of white blood cells or blood in the urine. Alternatively, the marker ingredient may be a combination of materials in which one ingredient interacts with a component of the urine to form an intermediate material which then interacts with another marker ingredient to generate the colour or visual change. An example of the latter is the interaction of glucose in the blood with glucose oxidase in the carrier member to form hydrogen peroxide which then reacts with toluidine in the carrier member to form a characteristic blue colour. For convenience, the invention will be described hereinafter in terms of the use of a mixture of glucose oxidase and toluidine to detect glucose in the urine.

The marker ingredient(s) are applied to the carrier medium in any suitable form so that collection of the urine from the patient brings the urine into contact with the marker ingredients. Thus, the carrier member may be a sheet of a

- 5 -

suitable polymer, for example the other polyethylene sheet layer of a composite diaper of incontinence pad structure, having the marker ingredient(s) applied thereto in a suitable binder composition. Alternatively, the marker ingredient(s) may be absorbed into the body of the absorbent pad of such a diaper or incontinence pad. For example, the marker ingredient(s) may be applied to a component of the pad during construction of the pad using conventional powder deposition techniques as are used to apply particulate super absorber materials to enhance the fluid uptake of the pad. If desired, the marker ingredient(s) may be applied in separate stages so that the initial interaction of the glucose in the urine takes place at the outer layer or layers of the diaper and the resultant hydrogen peroxide then migrates into the body of the pad to interact with the toluidine within the body of the pad. However, for ease of detection of the colour or visual change in the marker ingredient(s), it is preferred to apply these as a continuous or discontinuous layer or coating to an outer or external component of the pad structure. It is particularly preferred to apply the active marker ingredients in a liquid carrier containing a resinous binder to the inner or outer face of the next-to-the-skin water permeable layer of the composite pad or diaper structure.

The diaper or pad typically will comprise a single or multi-layer pad of fibrillated cellulosic fibres sandwiched between an inner, next-to-the-skin, water permeable layer and an outer water impermeable layer. Such forms of

- 6 -

construction are widely used in the manufacture of disposable diapers, sanitary pads or incontinence pads and it is particularly preferred to apply the marker ingredient(s) to the inner face of the water permeable sheet forming part of the next-to-the-skin layer of the diaper by roller or other applicators. It is particularly preferred to apply the marker ingredient(s) as a series of overlapping or discrete droplets using an ink jet printer.

As indicated above, the carrier member is preferably one of the layers of a composite absorbent pad diaper or incontinence pad which are to be worn by the patient, for example as a diaper, trainer pant or as an incontinence pad in a pair of water proof drawers or underpants. However, the invention can also be applied to other articles which are to be worn by the person, for example a colostomy or external urine collection bag. In such cases the bag is not in the form of an article of clothing as with a diaper, but is carried by the person and has the urine directly excreted into it. The term worn by the patient is therefore to be construed herein as including carrier members which are attached to the person and into or onto which the urine from the wearer is directly excreted and retained.

25

The marker ingredient(s) will usually be applied as a coating to part or all of that area of the carrier which is to receive the urine excreted from the patient. However, it is within the scope of the present invention for the carrier member to be a membrane or pad over or

30

- 7 -

through which the urine flows to the main receptacle which retains the urine. For example, the marker ingredient(s) can be applied to the inner face of the tube feeding the urine to the colostomy bag or can be impregnated into a pad within such a tube or in the neck of the colostomy bag.

For convenience, the invention will be described hereinafter in terms of a coating of the marker ingredient(s) on the water permeable layer of the diaper or pad.

As indicated above, the marker ingredient(s) are preferably applied to the water permeable layer using a roller or other conventional fluid application technique. It is particularly preferred to apply the marker ingredient(s) in a liquid carrier, for example an aqueous or solvent carrier, using an ink jet printer, for example using the on-line technique described in our European Patent No 0211524B. The use of an ink jet printer technique allows the marker ingredient(s) to be deposited on the carrier member in any suitable pattern and at application rates which may vary across the surface of the carrier member.

The amount and type of marker ingredient(s) which are applied to the surface of the carrier member will depend upon the nature of the marker ingredient(s), the component of the urine which is being monitored or detected and may be readily determined by simple trial and error tests. If

- 8 -

desired, the marker ingredient(s) may be deposited in a series of layers of different ingredients and the amount of marker ingredient(s) applied may vary over the surface of the carrier member to achieve different concentrations
5 across the surface of the carrier medium.

In addition to the marker ingredient(s) the material applied to the carrier member may contain other ingredients to enhance the utility of the coating or layer
10 applied to the carrier medium. For example, the material may contain one or more colour filter materials to screen out or reduce the effect of extraneous other ingredients. Thus, the material can incorporate a red colour filter medium so as to reduce the effect of blood in the urine
15 during menstrual cycles on the blue colour generated when testing for glucose in the urine. The material applied to the carrier member may contain one or more slow or delayed release materials which progressively dissolve or break down so as to permit progressive access of the urine to
20 the marker ingredient(s). In this way the blue colour for glucose in the urine can be generated by successive excretions of urine onto the carrier member and not just by the first excretion.

25 The invention thus provides a simple and effective means by which the presence of components in the urine of a patient can be monitored without the need for invasive blood sampling and which is inherently carried out at each urination by the patient without the need for the patient
30 to remember to take any specific action.

- 9 -

DESCRIPTION OF THE DRAWINGS:

The invention will now be described by way of illustration
5 with respect to a preferred embodiment thereof as shown in
the accompanying drawings in which Figure 1 is a
diagrammatic cross section through the absorbent pad of a
disposable diaper or incontinence pad to be worn in the
crotch area of a patient and to receive and contain urine
10 excreted from the patient; and Figure 2 is a cross section
through the mouth of a colostomy bag incorporating a pad
of foamed plastic or other material impregnated with a
marker ingredient and through which the urine must
percolate on its travel from the patient to the interior
15 of the colostomy bag.

DESCRIPTION OF THE PREFERRED EMBODIEMENT:

The absorbent pad of a diaper or incontinence pad
20 comprised a pad 1 of fibrillated cellulose fibres or other
fibrous mass sandwiched between an outer water impervious
polythene sheet layer 2 and a water pervious next-to-the-
skin woven material layer 3. Many forms of such structure
are known and used in the diaper or incontinence fields
25 and are suitable for present use. A coating 4 of glucose
oxidase and toluidine in a polyacrylic binder is applied to
part or all of the layer 3 in the crotch region of the
pad. The coating may be continuous or discontinuous and
is preferably applied as an aqueous solution on line using
30 an ink jet printer as the sheet of woven material 3 is fed

- 10 -

- to the process during which the composite fabric of the pad is formed during the manufacture of the diaper or incontinence pad. If desired, the coating can be dried using a hot air flow as the sheet 3 is fed into the diaper manufacture production process. Alternatively, the coating can be applied during production of sheet 3 prior to its subsequent transport to and use in the manufacture of the diaper.
- 10 In use, the pad is worn upon the crotch area of a patient and acts to receive and retain urine and faeces excreted by the patient. As the urine is excreted onto the layer 3 of the pad, any glucose in the urine reacts with the glucose oxidase in the coating 4 to release hydrogen peroxide which then reacts with the toluidine in the coating to generate a characteristic blue colouration. The patient or a nurse or other carer for the patient can then readily observe that this colour has been generated when the diaper or pad is removed from the patient. Where the coating contains the marker ingredient(s) incorporated into a slow release composition, this can be selected so that only some of the marker ingredient(s) are accessible initially by the urine and further marker ingredient(s) only become accessible at a later time. In this way, colour is developed initially in one area of the diaper or pad and subsequently in other areas enabling the user to determine the colour generation over a period of time and over more than one urine excretion.
- 30 If desired, the coating 4 can be formed on the inner face

- 11 -

of the outer layer 2 in addition to or in replacement for the coating on layer 3 so that the generation of the blue colour can be observed through layer 2 without the need to remove the diaper or pad from the patient.

5

In the embodiment shown in Figure 2, a patient wears a colostomy bag 10 connected by a tube 11 to his partially sectioned colon and excretes urine through tube 11 into bag 10. The neck 12 of the bag 10 is fitted with a foamed
10 plastic or other porous or foraminous plug 13 which has been impregnated with the mixture of glucose oxidase and toluidine. As the patient urinates, the glucose in the urine passing through plug 13 causes the generation of the characteristic blue colour.

15

The generation of the blue colour in coating 4 or plug 13 alerts the patient or a nurse caring for the patient that he has glucose in his urine so that remedial action can be taken. Alternatively, where the patient is known to have
20 glucose in his urine, for example due to diabetes, generation of a blue colour would be expected. However, a change in the hue of the colour indicates a change in the level of the glucose and hence a change in the patient's diabetic condition.

25

From another aspect, the invention thus provides a method for producing a carrier medium intended to be worn on a patient, which method comprises apply to that medium one or more marker ingredients which are to interact with a
30 component in a bodily fluid which is excreted by the

- 12 -

patient so as to generate a characteristic colour or other visible change.

5 The invention yet further provides a carrier medium to be worn upon the body of a mammal and having applied thereto one or more marker ingredients which are to interact with a component in a bodily fluid which is excreted by a mammal so as to generate a characteristic colour or other visible change.

- 13 -

CLAIMS:

1. A device for non-invasively detecting or monitoring a medical condition in a mammal, said device comprising a member adapted to be worn upon the body of the mammal to receive at least some of a bodily fluid excreted by the mammal, said member carrying one or more marker ingredients which interact with one or more components of the bodily fluid to generate a colour or other visible indication, said interaction being characteristic of the medical condition in the mammal.

2. A device according to claim 1 wherein said member comprises a bodily fluid absorbent pad sandwiched between an inner, next to the body, bodily fluid permeable layer, and an outer bodily fluid impermeable layer.

3. A device according to claim 2 wherein said one or more marker ingredients are applied to said inner layer.

4. A device according to claim 2 wherein said one or more marker ingredients are applied to the inner face of said outer layer, and are observable through said outer layer.

5. A device according to claim 2 wherein said one or more marker ingredients are applied to said absorbent pad.

6. A device according to claim 2 wherein said one or more marker ingredients comprises first and second marker

- 14 -

ingredients, said first marker ingredient is applied to either or both of said inner and outer layers, and said second marker ingredient is applied to said absorbent pad, interaction of said bodily fluid with said first marker
5 ingredient resulting in the migration into said absorbent pad of a substance which then interacts with said second marker ingredient to generate said colour or other visible indication.

10 7. A device according to claim 1 wherein said member comprises a bag or container worn by the mammal for collection of said bodily fluid.

15 8. A device according to claim 7 wherein said bag or container includes a component through which or over which said bodily fluid passes in receipt by said bag or container, said one or more marker ingredients being applied to said component.

20 9. A device according to claim 7 wherein a tube feeds said bodily fluid to said bag or container, and said one or more marker ingredients are applied to the inner face of the tube and/or a component within the tube.

25 10. A device according to any one of the preceding claims wherein said one or more marker ingredients are incorporated into a slow release composition so as to permit only progressive access of said bodily fluid to the marker ingredients thereby to provide detection or
30 monitoring of said medical condition over a relatively

- 15 -

lengthy period of time.

11. A device according to any one of the preceding
claims wherein said member in addition to carrying said
5 one or more marker ingredients also carries one or more
colour filter materials to screen out or reduce the visual
effect of extraneous components of said bodily fluid on
said colour or other visual indication of said medical
condition.

10

12. A device according to any one of the preceding
claims wherein said member is adapted to be worn upon the
body of a human to receive at least some of the urine
excreted by the human.

15

13. A non-invasive method for detecting or monitoring a
medical condition in a mammal, said method comprising
detecting a visual and/or colour change in a marker
ingredient which interacts with one or more components of
20 a bodily fluid excreted by the mammal to generate a colour
or other visible indication, said interaction being
characteristic of the medical condition in the mammal, the
marker ingredient being carried by a carrier member worn
by the mammal which receives at least part of the bodily
25 fluid excreted by the mammal.

14. A method for producing a device for non-invasively
detecting or monitoring a medical condition in a mammal,
which device comprises a member adapted to be worn upon
30 the body of the mammal to receive at least some of a

- 16 -

bodily fluid excreted by the mammal, said method comprising applying to that member one or more marker ingredients which are to interact with one or more components in the bodily fluid so as to generate a colour
5 or other visible indication, said interaction being characteristic of the medical condition in the mammal.

15. A method according to claim 14 wherein said marker ingredients are applied to said member by means of ink jet
10 printing and in a liquid carrier containing a resinous binder.

1/1

FIG. 1





FIG. 2



INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/002703

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61B10/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/02985 A (ROSENGREEN LEA T) 21 January 1999 (1999-01-21)	1,2,5, 12,14
Y	figures 2,3	15
X	WO 00/49948 A (UNIV ULSTER ;MULHOLLAND CLIVE WILLIAM (GB); NORTHROP CLEWES CHRIST) 31 August 2000 (2000-08-31)	1,2,5, 12,14
X	DE 100 16 383 A (SALING ERICH) 7 June 2001 (2001-06-07)	1-3,12, 14
X	DE 199 04 556 C (RAHE MARTIN) 6 July 2000 (2000-07-06)	1,2,4, 12,14
	column 3, line 54-67 figure 2	
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

30 June 2004

Date of mailing of the international search report

12/07/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schleßl, W

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/002703

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 35 04 527 A (MEDIZIN LABORTECHNIK VEB K) 6 February 1986 (1986-02-06)	1,7,8
Y	figure 1 ----	9
Y	DE 101 01 679 A (BOEHM NORBERT ;KINZL PETRA (DE)) 25 July 2002 (2002-07-25) paragraph '0019! ----	9
Y	EP 0 211 524 A (WILLETT INT LTD) 25 February 1987 (1987-02-25) cited in the application the whole document -----	15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/002703

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: ¹³
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/002703

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9902985	A	21-01-1999	AU 7832598 A WO 9902985 A1	08-02-1999 21-01-1999
WO 0049948	A	31-08-2000	AU 2679800 A WO 0049948 A2	14-09-2000 31-08-2000
DE 10016383	A	07-06-2001	DE 10016383 A1	07-06-2001
DE 19904556	C	06-07-2000	DE 19904556 C1 WO 0045705 A1 EP 1150609 A1	06-07-2000 10-08-2000 07-11-2001
DE 3504527	A	06-02-1986	DD 225337 A1 DE 3504527 A1 DK 302085 A	31-07-1985 06-02-1986 06-01-1986
DE 10101679	A	25-07-2002	DE 10101679 A1	25-07-2002
EP 0211524	A	25-02-1987	AT 67399 T AU 595812 B2 AU 5983886 A CA 1283814 C DE 3681530 D1 EP 0211524 A1 ES 2000652 A6 GB 2177977 A ,B JP 2536850 B2 JP 62069802 A MX 168260 B US 4909879 A	15-10-1991 12-04-1990 15-01-1987 07-05-1991 24-10-1991 25-02-1987 16-03-1988 04-02-1987 25-09-1996 31-03-1987 14-05-1993 20-03-1990